Stock Price, News, Quote and Profile of TRAWS PHARMA INC(NASDAQ:TRAW) stock

TRAWS PHARMA INC

NASDAQ:TRAW (12/20/2024, 8:00:01 PM)

After market: 5.02 0 (0%)

5.02

-0.31 (-5.9%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

GICS SubIndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-3730.43%

Sales Q2Q%0%

CRS0

6 Month979.57%

Overview

Earnings (Last)11-14 2024-11-14/amc

Earnings (Next)N/A N/A

Ins Owners27.01%

Inst Owners100.68%

Market Cap15.21M

Shares3.03M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts82.86

Short Float %0.36%

Short Ratio0.92

IPO07-25 2013-07-25

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Traws Pharma Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The firm is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

Company Info

TRAWS PHARMA INC

12 Penns Trail

Newtown PENNSYLVANIA

P: 12677593680

Employees: 16

Website: https://www.onconova.com/

TRAW News

a month ago - Traws Pharma, Inc.Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without...

2 months ago - Expert Systems, Inc.Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment

/PRNewswire/ -- Expert Systems, a leader in combining human and artificial intelligence to accelerate drug discovery, celebrates a key milestone in the...

2 months ago - Traws Pharma, Inc.Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy...

3 months ago - Traws Pharma, Inc.Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

TRAWS PHARMA INC (TRAW)

Nasdaq Stock Screener

USA Stock Screener